 Antineoplastic Agents, Hormonal
"Antineoplastic Agents, Hormonal" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antineoplastic agents that are used to treat hormone-sensitive tumors. Hormone-sensitive tumors may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumor regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumors may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukemias. (From AMA Drug Evaluations Annual 1994, p2079)
| Descriptor ID |
D018931
|
| MeSH Number(s) |
D27.505.954.248.169
|
| Concept/Terms |
Antineoplastic Agents, Hormonal- Antineoplastic Agents, Hormonal
- Hormonal Agents, Antineoplastic
- Hormonal Antineoplastic Agents
- Hormonal Antineoplastics
- Antineoplastic Hormonal Drugs
- Drugs, Antineoplastic Hormonal
- Hormonal Drugs, Antineoplastic
- Hormonal Antineoplastic Drugs
- Antineoplastics, Hormonal
- Antineoplastic Hormonal Agents
- Agents, Antineoplastic Hormonal
- Antineoplastic Drugs, Hormonal
|
Below are MeSH descriptors whose meaning is more general than "Antineoplastic Agents, Hormonal".
Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Agents, Hormonal".
This graph shows the total number of publications written about "Antineoplastic Agents, Hormonal" by people in this website by year, and whether "Antineoplastic Agents, Hormonal" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 1 | 2 | | 1997 | 1 | 0 | 1 | | 2002 | 0 | 1 | 1 | | 2004 | 0 | 1 | 1 | | 2005 | 1 | 1 | 2 | | 2006 | 0 | 1 | 1 | | 2009 | 1 | 0 | 1 | | 2012 | 1 | 0 | 1 | | 2013 | 2 | 2 | 4 | | 2015 | 0 | 2 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Antineoplastic Agents, Hormonal" by people in Profiles.
-
Hsu A, Belkin E, Han S, Pellish R. Tamoxifen-associated portal vein thrombosis causing severe oesophageal variceal bleeding. BMJ Case Rep. 2015; 2015.
-
Bostner J, Karlsson E, Eding CB, Perez-Tenorio G, Franzén H, Konstantinell A, Fornander T, Nordenskjöld B, Stål O. S6 kinase signaling: tamoxifen response and prognostic indication in two breast cancer cohorts. Endocr Relat Cancer. 2015 Jun; 22(3):331-43.
-
Kaufman SA, Harris EE, Bailey L, Chadha M, Dutton SC, Freedman GM, Goyal S, Halyard MY, Horst KC, Novick KL, Park CC, Suh WW, Toppmeyer D, Zook J, Haffty BG. ACR Appropriateness Criteria® Ductal Carcinoma in Situ. Oncology (Williston Park). 2015 Jun; 29(6):446-58, 460-1.
-
Williams KE, Anderton DL, Lee MP, Pentecost BT, Arcaro KF. High-density array analysis of DNA methylation in Tamoxifen-resistant breast cancer cell lines. Epigenetics. 2014 Feb; 9(2):297-307.
-
Lorange E, Harmanli O, Cao QJ, Jones KA. Vaginal myofibroblastoma with prostatic glands: is there an association with tamoxifen use? A case report. J Reprod Med. 2013 Jul-Aug; 58(7-8):344-6.
-
Qiu W, Wang X, Buchanan M, He K, Sharma R, Zhang L, Wang Q, Yu J. ADAR1 is essential for intestinal homeostasis and stem cell maintenance. Cell Death Dis. 2013 Apr 18; 4:e599.
-
Schoenfeld JD, Margalit DN, Kasperzyk JL, Shui IM, Rider JR, Epstein MM, Meisner A, Kenfield SA, Martin NE, Nguyen PL, Kantoff PW, Giovannucci EL, Stampfer MJ, Mucci LA. A single nucleotide polymorphism in inflammatory gene RNASEL predicts outcome after radiation therapy for localized prostate cancer. Clin Cancer Res. 2013 Mar 15; 19(6):1612-9.
-
Mehta NK, Malkani S, Ockene I. Spontaneous coronary artery dissection during cabergoline therapy. Tex Heart Inst J. 2012; 39(1):92-4.
-
Layeequr Rahman R, Crawford S. Chemoprevention Indication Score: a user-friendly tool for prevention of breast cancer - pilot analysis. Breast. 2009 Oct; 18(5):289-93.
-
Yood MU, Owusu C, Buist DS, Geiger AM, Field TS, Thwin SS, Lash TL, Prout MN, Wei F, Quinn VP, Frost FJ, Silliman RA. Mortality impact of less-than-standard therapy in older breast cancer patients. J Am Coll Surg. 2008 Jan; 206(1):66-75.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|